Skip to content
Medical Health Aged Care

Monash Expert: Senate inquiry into menopause

Monash University < 1 mins read

A Senate inquiry is set to examine the impact of menopause, and is due to report in September 2024. 

The terms of reference cover issues relating to perimenopause and menopause, including awareness, economic cost, physical impacts, mental and emotional wellbeing, caregiving responsibilities, government policies and programs, and cultural and societal factors 

Available to comment:

Professor Jayashri Kulkarni AM, Professor of Psychiatry and Director HER Centre Australia, Faculty of Medicine, Nursing and Health Sciences
Contact details: +61 429 028 852, jayashri.kulkarni@monash.edu 
Read more of Professor Kulkarni’s commentary atMonash Lens

  • Improving mental illness treatments
  • The relationship between hormones and mental illness in women
  • Menopause and mental illness
  • Women’s mental health

The following can be attributed to Professor Kulkarni:

“Depression and anxiety caused by hormone changes during the menopause transition are under recognised and treated poorly. As a result, many women suffer for years. This Senate Inquiry will hopefully assist in raising awareness and developing new approaches for women’s mental health issues especially related to menopause.”

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or media@monash.edu

More from this category

  • Medical Health Aged Care
  • 29/11/2023
  • 23:22
Clairvoyant Therapeutics

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints."We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out…

  • Medical Health Aged Care
  • 29/11/2023
  • 12:07
Hola Health

Leading health tech firm named among fastest-growing Australian start-ups

Hola Health, a leading local health tech start-up providing telehealth and online script fulfillment services to a growing number of Australians, has been named in the top 5 fastest-growing new companies in the country in a prestigious annual list. The Australian Financial Review’s Fast Starters list recognises Australia’s 100 fastest-growing start-ups and young companies.It shows Hola Health grew revenue from around $100,000 in 2020/21 to $3.8 million last financial year. It is on track to exceed $10 million in revenue by the end of this financial year. In naming Hola Health at number five on the list, the AFR hailed…

  • Contains:
  • Medical Health Aged Care
  • 29/11/2023
  • 07:34
Public Health Association of Australia / Australian and New Zealand Journal of Public Health

New research reveals how babies and toddlers are targeted with unhealthy foods

Wednesday 29 November 2023 Babies and toddlers can't read or buy food yet, but new research reveals that they are being targeted with aggressive marketing in the baby and toddler aisle at the supermarket. The research, published today in theAustralian and New Zealand Journal of Public Health,has prompted health experts to call for regulation of on-pack labelling and promotional techniques used on baby and toddler food. Authors analysed 230 product packs found in two major supermarkets to uncover the marketing techniques used by manufacturers of products for children aged from just six months to three years. They found that 9…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.